Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment

Mindfulness ◽  
2021 ◽  
Author(s):  
Fabio Giommi ◽  
Vittoria Castagner ◽  
Andrea Zaccaro ◽  
Angelo Gemignani ◽  
Alessandro Serretti ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Cognitive Therapy ◽  
Pharmacological Treatment

Anxiety in cardiology. The use of pregabalin in the treatment of anxiety disorders in patients with cardiovascular diseases

2021 ◽  
Vol 14 (4) ◽  
pp. 428-432
Author(s):  
Anna Antosik-Wójcińska
Keyword(s):  
Cardiovascular Diseases ◽  
Early Diagnosis ◽  
Anxiety Disorders ◽  
Pharmacological Treatment ◽  
Anxiety Symptoms ◽  
Health Consequences ◽  
Cardiovascular Patients ◽  
Starting Point ◽  
Patient Prognosis ◽  
High Level

The paper discusses two issues: the multidirectional relationship between the occurrence of anxiety symptoms and cardiovascular diseases, and the influence of the persistently high level of anxiety on the course of cardiological diseases and patient prognosis. In the discussion on the negative health consequences of anxiety disorders, there is emphasized importance of early diagnosis of these disorders and implementation of its treatment. As a starting point there were presented clinical cases of cardiovascular patients in whom developed anxiety disorders. The following sections discuss various aspects of the pharmacological treatment of anxiety disorders, focusing on the possible use of pregabalin in this.

S-17-1 Pharmacological treatment of anxiety disorders: An overview

1995 ◽  
Vol 5 (3) ◽  
pp. 206-207
Author(s):  
J.P. Lépine ◽  
A. Pelissolo
Keyword(s):  
Anxiety Disorders ◽  
Pharmacological Treatment

scholarly journals Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

2005 ◽  
Vol 19 (6) ◽  
pp. 567-596 ◽  
Author(s):  
David S. Baldwin ◽  
Ian M. Anderson ◽  
David J. Nutt ◽  
Borwin Bandelow ◽  
A. Bond ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Pharmacological Treatment ◽  
British Association ◽  
Evidence Based ◽  
Evidence Based Guidelines

Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency

2005 ◽  
Vol 20 (5-6) ◽  
pp. 431-441 ◽  
Author(s):  
B. Le Foll ◽  
P. Melihan-Cheinin ◽  
G. Rostoker ◽  
G. Lagrue ◽  
Keyword(s):  
Cognitive Therapy ◽  
Nicotine Dependence ◽  
Pharmacological Treatment ◽  
Smoking Status ◽  
Single Agent ◽  
Smoking Behavior ◽  
Developed Countries ◽  
Evidence Based ◽  
Health Products

AbstractTobacco use is the leading preventable cause of death in developed countries. Millions of smokers are willing to stop, but few of them are able to do so. Clinicians should only use approaches that have demonstrated their efficacy in helping patients to stop smoking. This article summarizes the evidence-based major findings and clinical recommendations for the treatment of tobacco dependence of the French Health Products Safety Agency (AFSSAPS). Clinicians should enquire about the smoking status of each patient and provide information about health consequence of smoking and effective treatments available. These treatments include counseling (mainly individual or social support and behavioral and cognitive therapy) and pharmacological treatment with either nicotine replacement therapy (NRT) or bupropion LP. Pharmacological treatments should be used only for proven nicotine dependence, as assessed by the Fagerstrom test for Nicotine Dependence. The choice of pharmacologic treatment depends of the patient's preference and history and of the presence of contra-indications. The clinician should start with a single agent, but these treatments may be used in combination. Smoking behavior is a chronic problem that requires long-term management and follow-up. Access to intensive treatment combining pharmacological treatment and extensive behavioral and cognitive therapy should be available for highly dependent patients.

Schema Theory and Schema Therapy in Mood and Anxiety Disorders: A Review

2011 ◽  
Vol 25 (4) ◽  
pp. 257-276 ◽  
Author(s):  
Lisa D. Hawke ◽  
Martin D. Provencher
Keyword(s):  
Anxiety Disorders ◽  
Personality Disorders ◽  
Cognitive Therapy ◽  
Schema Theory ◽  
Early Maladaptive Schemas ◽  
Schema Therapy ◽  
Maladaptive Schemas ◽  
Mood And Anxiety Disorders ◽  
Preliminary Research ◽  
The Individual

Schema theory was developed for patients with chronic psychological problems who fail to make significant gains in cognitive therapy. Although the theory has been applied most frequently to personality disorders, mood and anxiety disorders may also be a relevant application. This article reviews the literature applying schema theory to mood and anxiety disorders. The literature suggests that people with mood and anxiety disorders present high levels of early maladaptive schemas, some of which would appear to reflect the characteristics of the individual disorders. Preliminary research suggests that schema therapy may be successfully extended to mood and anxiety disorders. Further research is necessary to examine the utility of schema therapy for these clienteles and to identify the individuals who stand to benefit most.

Mindfulness-based cognitive therapy for youth with anxiety disorders at risk for bipolar disorder: a pilot trial

2015 ◽  
Vol 10 (5) ◽  
pp. 426-434 ◽  
Author(s):  
Sian Cotton ◽  
Christina M. Luberto ◽  
Richard W. Sears ◽  
Jeffrey R. Strawn ◽  
Lauren Stahl ◽  
...  
Keyword(s):  
At Risk ◽  
Bipolar Disorder ◽  
Anxiety Disorders ◽  
Cognitive Therapy ◽  
Pilot Trial

Psychosocial and pharmacological treatment for pediatric anxiety disorders

2006 ◽  
Vol 6 (11) ◽  
pp. 1707-1719 ◽  
Author(s):  
Paige H Fisher ◽  
Jonathan L Tobkes ◽  
Lauren Kotcher ◽  
Carrie Masia-Warner
Keyword(s):  
Anxiety Disorders ◽  
Pharmacological Treatment ◽  
Pediatric Anxiety ◽  
Pediatric Anxiety Disorders
Sign in / Sign up

Export Citation Format

Share Document